文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

转谷氨酰胺酶1（TGM1）在人类癌症中的致癌和免疫作用的泛癌分析

A pan-cancer analysis of the oncogenic and immunological roles of transglutaminase 1 (TGM1) in human cancer.

作者信息

Wu Ruicheng, Li Dengxiong, Zhang Shuxia, Wang Jie, Chen Kai, Tuo Zhouting, Miyamoto Akira, Yoo Koo Han, Wei Wuran, Zhang Chi, Feng Dechao, Han Ping

机构信息

Department of Urology, Institute of Urology, West China School of Medicine, West China Hospital, Sichuan University, Chengdu, 610041, China.

Research Core Facilities, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, People's Republic of China.

出版信息

J Cancer Res Clin Oncol. 2024 Mar 12;150(3):123. doi: 10.1007/s00432-024-05640-6.

DOI:10.1007/s00432-024-05640-6
PMID:38472489
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10933153/
Abstract

BACKGROUND: There is currently a limited number of studies on transglutaminase type 1 (TGM1) in tumors. The objective of this study is to perform a comprehensive analysis across various types of cancer to determine the prognostic significance of TGM1 in tumors and investigate its role in the immune environment. METHOD: Pan-cancer and mutational data were retrieved from the TCGA database and analyzed using R (version 3.6.4) and its associated software package. The expression difference and prognosis of TGM1 were examined, along with its correlation with tumor heterogeneity, stemness, mutation landscape, and RNA modification. Additionally, the relationship between TGM1 expression and tumor immunity was investigated using the TIMER method. RESULTS: TGM1 is expressed differently in various tumors and normal samples and is associated with the overall survival and progression-free time of KIRC, ACC, SKCM, LIHC, and STES. In LICH, we found a negative correlation between TGM1 expression and 6 indicators of tumor stemness. The mutation frequencies of BLCA, LIHC, and KIRC were 1.7%, 0.3%, and 0.3% respectively. In BLCA and BRCA, there was a significant correlation between TGM1 expression and the infiltration of CD4 + T cells, CD8 + T cells, neutrophils, and dendritic cells. CONCLUSION: TGM1 has the potential to serve as both a prognostic marker and a drug target.

摘要

背景：目前关于1型转谷氨酰胺酶（TGM1）在肿瘤中的研究数量有限。本研究的目的是对各种类型的癌症进行全面分析，以确定TGM1在肿瘤中的预后意义，并研究其在免疫环境中的作用。 方法：从TCGA数据库中检索泛癌和突变数据，并使用R（版本3.6.4）及其相关软件包进行分析。检测了TGM1的表达差异和预后，以及它与肿瘤异质性、干性、突变图谱和RNA修饰的相关性。此外，使用TIMER方法研究了TGM1表达与肿瘤免疫之间的关系。 结果：TGM1在各种肿瘤和正常样本中的表达不同，并且与肾透明细胞癌（KIRC）、腺样囊性癌（ACC）、皮肤黑色素瘤（SKCM）、肝癌（LIHC）和睾丸胚胎性癌（STES）的总生存期和无进展生存期相关。在肝癌中，我们发现TGM1表达与6个肿瘤干性指标呈负相关。膀胱癌（BLCA）、肝癌和肾透明细胞癌的突变频率分别为1.7%、0.3%和0.3%。在膀胱癌和乳腺癌（BRCA）中，TGM1表达与CD4 + T细胞、CD8 + T细胞、中性粒细胞和树突状细胞的浸润之间存在显著相关性。 结论：TGM1有潜力作为一种预后标志物和药物靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b493/11793418/fd508b2b139b/432_2024_5640_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b493/11793418/04c266e5d7dd/432_2024_5640_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b493/11793418/2b4f3ac4a3f8/432_2024_5640_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b493/11793418/66c86651e902/432_2024_5640_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b493/11793418/f9a02172f35c/432_2024_5640_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b493/11793418/d48caf548f5a/432_2024_5640_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b493/11793418/3aca4d6893bd/432_2024_5640_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b493/11793418/fd508b2b139b/432_2024_5640_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b493/11793418/04c266e5d7dd/432_2024_5640_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b493/11793418/2b4f3ac4a3f8/432_2024_5640_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b493/11793418/66c86651e902/432_2024_5640_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b493/11793418/f9a02172f35c/432_2024_5640_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b493/11793418/d48caf548f5a/432_2024_5640_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b493/11793418/3aca4d6893bd/432_2024_5640_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b493/11793418/fd508b2b139b/432_2024_5640_Fig7_HTML.jpg

相似文献

[1]
A pan-cancer analysis of the oncogenic and immunological roles of transglutaminase 1 (TGM1) in human cancer.

J Cancer Res Clin Oncol. 2024-3-12

[2]
A pan-cancer analysis of the oncogenic role of zinc finger protein 419 in human cancer.

Front Oncol. 2022-12-12

[3]
Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.

Front Immunol. 2021

[4]
A pan-cancer analysis of the oncogenic and immunological roles of apolipoprotein F (APOF) in human cancer.

Eur J Med Res. 2023-6-14

[5]
[Pan-cancer analysis of ubiquitin-specific protease 7 and its expression changes in the carcinogenesis of scar ulcer].

Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi. 2023-6-20

[6]
Pan-cancer analysis of prognostic and immunological role of DTYMK in human tumors.

Front Genet. 2022-9-8

[7]
Stromal Interaction Molecule 1 (STIM1) is a Potential Prognostic Biomarker and Correlates with Immune Infiltrates in Solid Tumors.

J Environ Pathol Toxicol Oncol. 2023

[8]
Pan-cancer and single-cell analysis reveal dual roles of lymphocyte activation gene-3 (LAG3) in cancer immunity and prognosis.

Sci Rep. 2024-10-15

[9]
Comprehensive analysis about prognostic and immunological role of WTAP in pan-cancer.

Front Genet. 2022-9-6

[10]
BRCA1-Associated Protein Is a Potential Prognostic Biomarker and Is Correlated With Immune Infiltration in Liver Hepatocellular Carcinoma: A Pan-Cancer Analysis.

Front Mol Biosci. 2020-11-2

引用本文的文献

[1]
RAP1GAP is a prognostic biomarker and correlates with immune infiltrates in bladder cancer.

Discov Oncol. 2025-5-22

[2]
Transglutaminase 1: Emerging Functions beyond Skin.

Int J Mol Sci. 2024-9-25

[3]
Exploring the role of ADAMTSL2 across multiple cancer types: A pan-cancer analysis and validated in colorectal cancer.

Discov Oncol. 2024-10-9

本文引用的文献

[1]
Targeting the epigenome to reinvigorate T cells for cancer immunotherapy.

Mil Med Res. 2023-12-4

[2]
The Largest Chinese Cohort Study Indicates Homologous Recombination Pathway Gene Mutations as Another Major Genetic Risk Factor for Colorectal Cancer with Heterogeneous Clinical Phenotypes.

Research (Wash D C). 2023-10-17

[3]
TGM1 could predict overall survival for patients with urinary bladder cancer.

Asian J Surg. 2023-11

[4]
Cutaneous melanoma.

Lancet. 2023-8-5

[5]
Transglutaminase 2 is associated with adverse colorectal cancer survival and represents a therapeutic target.

Cancer Gene Ther. 2023-10

[6]
Effect of microbiome group on immune checkpoint inhibitors in treatment of gastrointestinal tumors.

Chin J Cancer Res. 2023-6-30

[7]
Comprehensive analysis of the role of immune-related PANoptosis lncRNA model in renal clear cell carcinoma based on RNA transcriptome and single-cell sequencing.

Oncol Res. 2023

[8]
Expression of m6A RNA Methylation Regulators and Their Clinical Predictive Value in Intrahepatic Cholangiocarcinoma.

Front Biosci (Landmark Ed). 2023-6-27

[9]
A pan-cancer analysis of the oncogenic and immunological roles of apolipoprotein F (APOF) in human cancer.

Eur J Med Res. 2023-6-14

[10]
Review and prospect of immune checkpoint blockade therapy represented by PD-1/PD-L1 in the treatment of clear cell renal cell carcinoma.

Oncol Res. 2023

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索